Sections
Health
Pharma
Biotech
Politics
In the Lab
First Opinion
The Watchdogs
Topics
Biotechnology
Cancer
CRISPR
Drug Development
Drug Pricing
Infectious Disease
Opioids
Pharmaceuticals
Public Health
Trump
Multimedia
The Readout LOUD
Science Happens!
Explainers
Boddities
All Video
Newsletters
More
Events
STAT Wunderkinds
Job Board
STAT Madness
Most Popular
Log in
Subscribe
Newsletters
Try STAT Plus
Newsletters
Try STAT Plus
The Pharmalot View
By
Ed Silverman
The Pharmalot View
From zero to hero: J&J CEO praises Trump one year after chastising him
By
Ed Silverman
The Pharmalot View
When modest is actually excessive: AstraZeneca spins its price hikes
By
Ed Silverman
advertisement
The Pharmalot View
He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices
By
Ed Silverman
advertisement
The Pharmalot View
Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising
By
Ed Silverman
The Pharmalot View
Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines
By
Ed Silverman
The Pharmalot View
The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous
By
Ed Silverman
The Pharmalot View
California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference
By
Ed Silverman
advertisement
The Pharmalot View
Here’s how a loophole in a transparency law can distort medical practices
By
Ed Silverman
advertisement
The Pharmalot View
This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
By
Ed Silverman
The Pharmalot View
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
By
Ed Silverman
The Pharmalot View
Drug makers deserve to be publicly shamed for thwarting competition from generics
By
Ed Silverman
The Pharmalot View
The art of the deal? Why a money-back guarantee for drugs is a bad idea
By
Ed Silverman
The Pharmalot View
If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon
By
Ed Silverman
The Pharmalot View
It’s time to make it legal for Americans to order prescription drugs from abroad
By
Ed Silverman
The Pharmalot View
US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it
By
Ed Silverman
The Pharmalot View
The Trump administration could bring down drug prices. But it would take guts
By
Ed Silverman
The Pharmalot View
Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life
By
Ed Silverman
The Pharmalot View
How a $37,000-a-year medicine sets a good model for drug pricing
By
Ed Silverman
The Pharmalot View
Here’s one drug safety rule the FDA should enact — quickly
By
Ed Silverman
The Pharmalot View
Dear Mr. President: Your view of the FDA is misguided. Here’s why
By
Ed Silverman
The Pharmalot View
Dear Vice President Pence: Stop peddling false hopes to dying patients
By
Ed Silverman
The Pharmalot View
Pharma trade group vows to review membership criteria, but is this an empty promise?
By
Ed Silverman
The Pharmalot View
Dear President Trump: Your big idea on drug pricing is half-baked
By
Ed Silverman
The Pharmalot View
Drug industry ad campaign may be too late to save its reputation
By
Ed Silverman
The Pharmalot View
Trump is considering a radical to lead FDA. That’s dangerous for public health
By
Ed Silverman
The Pharmalot View
Trump should be good medicine for the pharmaceutical industry. Here’s why
By
Ed Silverman
The Pharmalot View
Pharma may have defeated Prop 61, but state battles over pricing will continue
By
Ed Silverman
The Pharmalot View
Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?
By
Ed Silverman
The Pharmalot View
Health officials should reject latest gambit by EpiPen maker to feed at the public trough
By
Ed Silverman
Next Page »
Sign up for our Morning Rounds newsletter
Your daily dose of what’s new in health and medicine.
Industry
Please select
Academia
Advertising/Marketing
Advocacy
Biotech
Consultancy/Firm
Financial Services
Government
Healthcare Payer
Healthcare Provider
Media
Medical Device
Non-profit
Pharma
Technology
Privacy Policy
Leave this field empty if you're human:
